The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.
about
Targeted Delivery Systems for Molecular Therapy in Skeletal DisordersThe potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivoCell delivery of therapeutic nanoparticlesRole of surface charge in determining the biological effects of CdSe/ZnS quantum dotsMacrophages recognize size and shape of their targetsDesign strategies and applications of circulating cell-mediated drug delivery systemsLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept.Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization.Preparation and properties of liposome-associated gentamicin.Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in AtherosclerosisEffects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomesLiposomes: applications in medicine.Influence of charge on FITC-BSA-loaded chondroitin sulfate-chitosan nanoparticles upon cell uptake in human Caco-2 cell monolayers.Vehicles for oligonucleotide delivery to tumours.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles.Cell-mediated drug delivery.Fate of lipid vesicles in vivo: a gamma-ray perturbed angular correlation study.Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study.Development of new derivatives of primaquine by association with lysosomotropic carriers.Biomaterial Strategies for Immunomodulation.Antibiological barrier nanovector technology for cancer applications.Conventional liposome performance and evaluation: lessons from the development of Vescan.Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization.Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.Nanomaterials for cancer therapy and imaging.Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyDrug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Multifunctional dendritic polymers in nanomedicine: opportunities and challenges.Liposome technology for cardiovascular disease treatment and diagnosis.Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking.Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.Application of liposomes in medicine and drug delivery.Encapsulated hemoglobin: current issues and future goals.Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy.Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p-shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study.Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers.Lipid nanoparticle delivery systems for siRNA-based therapeutics.
P2860
Q26752158-EC2CF6FB-0D28-4BBF-BD07-8231D39FD2A4Q26827175-4513496D-10F5-48C8-9D6D-F8C80FF42162Q28385606-74384477-D22C-42E3-BC6F-EBCC0495BE08Q28394457-340F504D-2CF7-4D3A-9B34-EADFA429F9D1Q28473589-CDA60337-5A2B-478E-8EE7-0B5C8D54CB51Q28547179-6572C1A8-0975-4610-BF8E-C821F9F06FDDQ30366990-08CCC9FA-1C48-46A1-9E70-DA0FDF4E3480Q33533706-9C0894C3-501B-4A2D-911A-CF3D38E11002Q33633359-5CC1B05F-1A8E-4A1A-AF8E-D73DACE3EE28Q33726411-73A2D3E4-E1CF-4B4A-B1BE-7065AA3A6047Q33856678-FA336EA3-8077-4E25-8BE5-F32BA944AE90Q34177514-908E23EA-E6D4-4563-ABB1-42D416BCF141Q34320703-DE920EE7-E7C1-4DC7-AD82-052398893D25Q34426254-EA429F5C-23F4-4A58-87D9-FA23177E5541Q34518719-779C8B0A-C23D-49A5-BA84-65E27D34B8F5Q34548430-C5D0E68E-8F67-4421-B1A9-05C3D00B5D50Q34659759-3A8E0C6B-3903-4DE8-80E1-B76DDF99034BQ34709440-2E33F86C-8733-4456-B87D-1A0529903421Q35061375-55C8F4E8-DF1C-4EBB-9CFC-8D13E9E46004Q36397370-0164AEB0-2A5F-4C1B-81E8-1EC7E9C837A7Q36675517-DDCA9160-7D86-453C-989D-070B6ECFDE7AQ36703124-943AB60F-A295-431E-9BDE-8533E655456DQ36903797-4375B288-32A7-45F4-A83D-381CA61C5BB4Q37008683-4886AD23-4E08-468F-966F-BAE7C3239533Q37065779-F8E4EC10-7C9F-4F4C-A1A4-A5D8E45E18ADQ37362790-273CEC7B-D4B6-418B-A8F8-F134372380BBQ37601740-8EC1205B-D668-4F0B-B4C2-7B7F738765D0Q37650345-3354CA20-B657-4A50-BCFE-8BCB52763C29Q37845396-39D97AE1-0548-4A99-BB9A-CE3AD0B0A814Q37967150-F4DEB576-CF42-4D82-9F57-FD7255E11F95Q37974931-052E48FC-4FAC-483C-A6B9-9A6A471EF3ABQ38047267-AFF3E1FF-1696-474C-AC94-1E2B7C45FA20Q38074442-5827CE19-A729-4DB6-AF78-B7990D8EB746Q38249220-305447A7-695A-41EF-A881-E8996986E8B0Q38569496-8E90C53D-6743-409F-A7CB-0BA2A9251170Q38574683-DE73091E-8A6C-4D5A-9D32-241607780DEFQ39011082-90C04CA2-A21A-4B53-A957-CA0D32C8A4B8Q39014487-B187D815-41DA-4A13-9CAC-6A68D2B38987Q39027489-CB36165E-5FCA-458A-8CD2-87C43609F23EQ39027758-AE2E17D0-FCFD-475B-88BA-9E70D052B57D
P2860
The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年学术文章
@wuu
1975年学术文章
@zh
1975年学术文章
@zh-cn
1975年学术文章
@zh-hans
1975年学术文章
@zh-my
1975年学术文章
@zh-sg
1975年學術文章
@yue
1975年學術文章
@zh-hant
name
The effect of particle size an ...... d liposome encapsulated drugs.
@en
The effect of particle size an ...... d liposome encapsulated drugs.
@nl
type
label
The effect of particle size an ...... d liposome encapsulated drugs.
@en
The effect of particle size an ...... d liposome encapsulated drugs.
@nl
prefLabel
The effect of particle size an ...... d liposome encapsulated drugs.
@en
The effect of particle size an ...... d liposome encapsulated drugs.
@nl
P1476
The effect of particle size an ...... d liposome encapsulated drugs.
@en
P2093
P304
P356
10.1016/S0006-291X(75)80433-5
P407
P577
1975-04-01T00:00:00Z